<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02311985</url>
  </required_header>
  <id_info>
    <org_study_id>2048-14</org_study_id>
    <nct_id>NCT02311985</nct_id>
  </id_info>
  <brief_title>Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial</brief_title>
  <acronym>POCKET</acronym>
  <official_title>Point-of-care Versus Standard Coagulation Tests Versus Restrictive Strategy to Guide Transfusion in Chronic Liver Failure Patients Requiring Central Venous Line: Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare three different blood transfusion strategies for
      coagulopathy correction before central venous catheterization in patients with chronic liver
      failure (cirrhosis and/or chronic liver graft dysfunction) admitted in intensive care unit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central venous catheterization is a ubiquitous procedure in intensive care units and is
      mainly used for drug administration, hemodynamic monitoring and hemodialysis. Only in US more
      than five million catheters are inserted annually. One of the main complications associated
      to central venous lines are the mechanical ones, i.e. arterial puncture, bleeding and
      hematoma formation, which varies between 5% and 19%. The use of real-time ultrasonography to
      accomplish central venous catheterization was associated to a drastic reduction in
      complication rates, and when performed by trained personnel, some series show complications
      rates &lt;1%, even in patients with coagulopathy.

      Patients presenting with chronic liver failure has a complex coagulation system balance,
      resulting from reduction in the majority of procoagulant and anticoagulant factors, opposed
      by preservation of thrombin generation. Thus, these patients are prone to develop hemorrhagic
      and thrombotic phenomena. The coagulation of cirrhotic patients have been classically
      evaluated by standard coagulation tests. Nevertheless, these tests present important
      limitations, as evaluation of plasmatic component only, and do not predict bleeding risk. The
      thromboelastometry is a point-of-care real-time coagulation system evaluation with the
      advantage of evaluating the cellular and plasmatic components of the coagulation and present
      a more comprehensive evaluation of blood coagulation, specially in cirrhotics. This
      technology is associated with reduced costs in diverse clinical settings.

      In clinical practice, approximately 90% of physicians empirically transfuse blood components
      to cirrhotic patients before invasive procedures. This practice is associated to increased
      risks related to blood transfusion per se, e.g. blood borne infections, immunologic and
      non-immunologic adverse reactions, to cite some. Several randomized clinical trials have
      shown that restrictive blood transfusion strategies are associated to better outcomes,
      including mortality.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low inclusion rate
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients submitted to blood components transfusion - i.e. fresh frozen plasma, platelets and/or cryoprecipitate - before central venous catheterization</measure>
    <time_frame>Day of randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemorrhagic complications associated to central venous catheterization procedure</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute immunologic and non-immunologic adverse effects of blood transfusion</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs assessments (laboratory and blood transfusion) between the three strategies</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>Up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>Up to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Coagulogram-based protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm based on standard coagulation tests protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thromboelastometry-based protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm based on rotational thromboelastometry (ROTEM(R)) protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrictive strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm based on a restrictive protocol strategy based on INR/PT and platelets count. The possible components to be used include fresh frozen plasma and/or platelets (random or aphaeresis).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Coagulogram-based protocol</intervention_name>
    <description>The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR &gt;1.5 or PTT &gt;50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets &lt;50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen &lt;150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).</description>
    <arm_group_label>Coagulogram-based protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Thromboelastometry-based protocol</intervention_name>
    <description>The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex &lt;80 sec. and A10ex &gt;40 mm, then no blood transfusion is performed; when CTex &gt;80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex &lt;40 mm or A10fib &gt;10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex &lt;40 mm or A10fib &lt;10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).</description>
    <arm_group_label>Thromboelastometry-based protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Restrictive strategy</intervention_name>
    <description>The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR &gt;5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets &lt;25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).</description>
    <arm_group_label>Restrictive strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic liver failure (cirrhosis or chronic graft dysfunction) from any cause and
             medical indication of central venous line placement

        Exclusion Criteria:

          -  Acute liver failure or

          -  Use of therapeutic doses of oral or parenteral anticoagulants (unfractionated heparin
             or low molecular weight heparin or oral anticoagulants) or

          -  Use of oral or parenteral platelet aggregation inhibitors or

          -  Patients with von Willebrand syndrome or

          -  Over-the-guidewire central venous catheter changing

          -  Patients previously included in this study protocol during the same hospital stay
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliezer Silva, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05652-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003 Mar 20;348(12):1123-33. Review.</citation>
    <PMID>12646670</PMID>
  </reference>
  <reference>
    <citation>Tercan F, Ozkan U, Oguzkurt L. US-guided placement of central vein catheters in patients with disorders of hemostasis. Eur J Radiol. 2008 Feb;65(2):253-6. Epub 2007 May 4.</citation>
    <PMID>17482407</PMID>
  </reference>
  <reference>
    <citation>Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011 Jul 14;365(2):147-56. doi: 10.1056/NEJMra1011170. Review.</citation>
    <PMID>21751907</PMID>
  </reference>
  <reference>
    <citation>Stravitz RT. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol (N Y). 2012 Aug;8(8):513-20.</citation>
    <PMID>23293564</PMID>
  </reference>
  <reference>
    <citation>Segal JB, Dzik WH; Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion. 2005 Sep;45(9):1413-25. Review.</citation>
    <PMID>16131373</PMID>
  </reference>
  <reference>
    <citation>Schöchl H, Nienaber U, Maegele M, Hochleitner G, Primavesi F, Steitz B, Arndt C, Hanke A, Voelckel W, Solomon C. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care. 2011;15(2):R83. doi: 10.1186/cc10078. Epub 2011 Mar 4.</citation>
    <PMID>21375741</PMID>
  </reference>
  <reference>
    <citation>Watson DM, Stanworth SJ, Wyncoll D, McAuley DF, Perkins GD, Young D, Biggin KJ, Walsh TS. A national clinical scenario-based survey of clinicians' attitudes towards fresh frozen plasma transfusion for critically ill patients. Transfus Med. 2011 Apr;21(2):124-9. doi: 10.1111/j.1365-3148.2010.01049.x. Epub 2010 Nov 10.</citation>
    <PMID>21062383</PMID>
  </reference>
  <reference>
    <citation>Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll D; Intensive Care Study of Coagulopathy (ISOC) investigators. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Crit Care. 2011;15(2):R108. doi: 10.1186/cc10129. Epub 2011 Apr 5.</citation>
    <PMID>21466676</PMID>
  </reference>
  <reference>
    <citation>Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999 Feb 11;340(6):409-17. Erratum in: N Engl J Med 1999 Apr 1;340(13):1056.</citation>
    <PMID>9971864</PMID>
  </reference>
  <reference>
    <citation>Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH, Fukushima J, Kalil Filho R, Sierra DB, Lopes NH, Mauad T, Roquim AC, Sundin MR, Leão WC, Almeida JP, Pomerantzeff PM, Dallan LO, Jatene FB, Stolf NA, Auler JO Jr. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010 Oct 13;304(14):1559-67. doi: 10.1001/jama.2010.1446.</citation>
    <PMID>20940381</PMID>
  </reference>
  <reference>
    <citation>Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J; FOCUS Investigators. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011 Dec 29;365(26):2453-62. doi: 10.1056/NEJMoa1012452. Epub 2011 Dec 14.</citation>
    <PMID>22168590</PMID>
  </reference>
  <reference>
    <citation>Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, Guarner-Argente C, Santaló M, Muñiz E, Guarner C. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21. doi: 10.1056/NEJMoa1211801. Erratum in: N Engl J Med. 2013 Jun 13;368(24):2341.</citation>
    <PMID>23281973</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Israelita Albert Einstein</investigator_affiliation>
    <investigator_full_name>Leonardo Lima Rocha, MD</investigator_full_name>
    <investigator_title>Adult Critical Care Medicine Attending Physician</investigator_title>
  </responsible_party>
  <keyword>Liver cirrhosis</keyword>
  <keyword>Blood coagulation</keyword>
  <keyword>Thromboelastography</keyword>
  <keyword>Blood transfusion</keyword>
  <keyword>Catheterization, central venous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

